

**REMARKS**

In reviewing this application subsequent to allowance applicants noted an omission in new claim 28. Specifically, the claim omits two "provisos" in the last section. The first added disclaimer is included in the claim in order to exclude compound numbers 13-14 of Shinagawa et al while the fifth disclaimer is added to exclude compound 18 of Shinagawa et al.

In the remarks portion of the amendment filed August 7, 2001, page 12 last three paragraphs I mentioned that these disclaimers were part of new claim 28, however, inadvertently these provisos were not included in the text of claim 28.

It is proposed now to include these two provisos to accomplish the objective stated in the amendment and response of August 7, 2001.

No new matter is involved and this will not require an additional search on the examiner's part.


Entry of this amendment is solicited.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_




Arthur K. Crawford  
Reg. No. 25,327

ARC:pfc  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

28. (Amended) A compound of formula (I)



wherein:  $X^+$  is  $N^+(R_1, R_2, R_3)$ , wherein

$R_1, R_2, R_3$ , being the same or different, are selected in the group consisting of hydrogen, a  $C_1$ - $C_9$  straight or branched alkyl group,  $-CH=NH(NH_2)$ ,  $-NH_2$ , and  $-OH$ ; or one or more  $R_1, R_2$  and  $R_3$ , together with the nitrogen atom which they are linked to, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic system; with the proviso that at least one of the  $R_1, R_2$  and  $R_3$  is different from hydrogen;

$Z$  is selected from

$-OR_4$ ,

$-OCOOR_4$ ,

$-OCONHR_4$ ,

$-OCSNHR_4$ ,

$-OCSOR_4$ ,

$-NHR_4$ ,

$-NHCOR_4$ ,

-NHCSR<sub>4</sub>,  
-NHCOOR<sub>4</sub>,  
-NHCSOR<sub>4</sub>,  
-NHCONHR<sub>4</sub>,  
-NHCSNHR<sub>4</sub>,  
-NHSOR<sub>4</sub>,  
-NHSONHR<sub>4</sub>,  
-NHSO<sub>2</sub>R<sub>4</sub>,  
-NHSO<sub>2</sub>NHR<sub>4</sub>, and  
-SR<sub>4</sub>,

wherein -R<sub>4</sub> is a C<sub>1</sub>-C<sub>20</sub> saturated or unsaturated, straight or branched alkyl group, optionally substituted with an A<sub>1</sub> group, wherein A<sub>1</sub> is selected from the group consisting of a halogen atom, or an aryl, heteroaryl, aryloxy or heteroaryloxy group, said aryl, heteroaryl, aryloxy or heteroaryloxy groups being optionally substituted with one or more C<sub>1</sub>-C<sub>20</sub> saturated or unsaturated, straight or branched alkyl or alkoxy group and/or halogen atom;

Y<sup>-</sup> is selected from the group consisting of -COO<sup>-</sup>, PO<sub>3</sub>H<sup>-</sup>, -OPO<sub>3</sub>H<sup>-</sup>, tetrazolate-5-yl;

with the proviso that when Z is -NHCOR<sub>4</sub>, Y is -COO<sup>-</sup>, then R<sub>4</sub> is C<sub>20</sub> alkyl;

with the proviso that when Z is -NHSO<sub>2</sub>R<sub>4</sub>, Y<sup>-</sup> is -COO<sup>-</sup>, then R<sub>4</sub> is not tolyl;

with the proviso that when Z is -NHCOOR<sub>4</sub>, Y is -COO, then R<sub>4</sub> is not CH<sub>3</sub> and C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>;

with the proviso that when Z is -NHR<sub>4</sub>, Y is -COO, then R<sub>4</sub> is not CH<sub>3</sub>,

with the proviso that when Z is -NHR<sub>4</sub>, X<sup>+</sup> is trimethylammonium and Y<sup>-</sup> is -COO<sup>-</sup>, then R<sub>4</sub> is not C<sub>1</sub>-C<sub>6</sub> alkyl,

their (R,S) racemic mixtures, their single R or S enantiomers, or their pharmaceutically acceptable salts .